The 5th “Future Healthcare VB100 Conference" with the theme of "Calculation of Life" grandly opened in Suzhou. The conference was hosted by VCBeat and co-hosted by Wujiang District People's Government of Suzhou and Zhong Nanshan Medical Foundation of Guangdong Province. The conference authority released the "China Future Healthcare Rankings 2020-2021", Biosis Healing was listed on the "TOP100 Medical Device Companies", at the same time, it was also the second time Biosis Healing landed on the list.
About the China Future Healthcare Rankings:
China Future Healthcare Rankings, founded in 2015, launched by VCBeat, VB100, and VCBeat Research Institute. It’s the first domestic innovative medical field list for unlisted companies, focusing on selection innovative medical practitioners in China which really represents the future healthcare, finding the core power of the future medical industry in China, promoting the innovation process of healthcare industry. The companies on the rankings is assessed through the VB100 value evaluation model. The rankings take company's latest valuation as the core assessment indicator, comprehensive referring for four primary indicators of enterprises in human resources, knowledge resources and important partner resources and market performance , and a total of 17 secondary indexes. Through the enterprise registration, agency recommended, cross check and expert review and other processes, in the end, award-winning companies on China Future Healthcare Rankings and subdivision awards are evaluated under fair and impartial assessment.
The year 2020 is still the year of the rise of biotechnology field, as a pioneer in the field of biotechnology, Biosis Healing has withstood the harsh test during the COVID-2019 pandemic. Biosis Healing SIS biomaterial products, with independent intellectual property rights, performed well in 2020 and the first quarter of 2021. SIS materials hernia repair mesh were awarded the "Beijing New Technology and New Product (Service) Certificate" and obtained the EU CE Certificate, which is also the first CE certificate for animal-derived mesh products in China; SIS material dura repair mesh, obtained the Class III medical device registration from China National Medical Products Administration, which is also the first dura product of non-crosslinked extracellular matrix derived biomaterial in China. A number of papers with SIS materials as the research object were included in the authoritative SCI core journals. It means that our research results in the field of biomaterials have been in a leading position in the world and won international recognition.
At this moment of achievement, the achievement belongs to the past. In the future, Biosis Healing will continue to work hard in the field of SIS biomaterials, pay attention to the basic research of SIS biomaterials. recruit high-end talents, adhere to the corporate development strategy of "talent-oriented, research and development first, and innovation based", continue to strengthen the combination of industry, education, research and medicine, closely unite with universities, scientific research institutions and hospitals to participate in the research and development of key common problems and cutting-edge core technologies in the field of SIS materials, and strive to develop more and better products for the benefit of patients.
版权所有®2019BIOSISHEALING